post-bg-419
calendary January 9, 2025

Discontinuation of semaglutide therapy leads to weight gain.

Semaglutide reduces total body weight and adipose tissue mass, reducing energy consumption. This mechanism affects the overall decrease in appetite, including increased satiety signals and attenuation of hunger signals, as well as improved control of food intake and reduced cravings for food. In addition, semaglutide reduces the preference for eating high-fat foods. 

Nevertheless, a study by Northwestern University in the USA showed that the majority of patients (up to 85%) stop taking GPP-1 agonists during the first two years due to the high cost of the drug (in the Russian Federation, the cost of GPP-1 drugs is several thousand rubles per package with 1 syringe pen) or due to with the achievement of the target weight. Subsequently, they regain up to 67% of the lost body weight and note a deterioration in their health. 

Weight gain has also been noted in other studies. For example, in 2022, most participants in the STEP-1 clinical trial regained up to 2/3 of their previously lost weight a year after giving up the drug. 

In Russia, semaglutide preparations are represented by seven trade names. Five drugs are produced in Russia, the other two in Denmark. 

It is worth noting that the documentation for consumers (instructions for medical use, leaflet) indicates that semaglutide preparations are indicated for use in patients with type 2 diabetes mellitus on the background of diet and exercise. Weight loss requires a comprehensive approach. 

There are no miracles.

 

 

References:
  1. https://jamanetwork.com/journals/jama/article-abstract/2826198
  2. https://pharmvestnik.ru/content/news/Bolshinstvo-pacientov-vnov-nabiraut-ves-posle-prekrasheniya-terapii-semaglutidom.html
  3. https://grls.rosminzdrav.ru/

More related posts

new-img-1

Control

Fine for spa resort in Yessentuki

Roszdravnadzor has imposed a fine of 130 thousand rubles on a spa resort in Yessentuki for improper storage of medical products…

03.03.2016
READ ARTICLE
new-img-2

Roszdravnadzor

Roszdravnadzor – patients’ rights

In 2015, Roszdravnadzor restored the rights of more than 460 thousand citizens to effective, accessible, and safe medical…

03.03.2016
READ ARTICLE
new-img-3

Regulation

The certification scheme for medical products hasn’t changed recently

Roszdravnadzor informs that the certification scheme for products in the Russian Federation is determined by Decree of the…

03.04.2016
READ ARTICLE
new-img-4

Control

Fines – Rostov region

In one and a half months of 2016, the Local Agency of Roszdravnadzor in Rostov Region imposed fines of the total amount of…

03.10.2016
READ ARTICLE
new-img-5

Control

Unregistered medical products

Two citizens were fined for selling unregistered medicinal products on the Internet in the Republic of Bashkortostan.

03.10.2016
READ ARTICLE
new-img-6

Control

Unscheduled inspection by roszdravnadzor

Roszdravnadzor started an unscheduled inspection of the Federal State-Funded Institution of Sverdlovsk Region Kirovgrad Central…

03.14.2016
READ ARTICLE
new-img-7

Medical Devices

International medical device regulators forum (IMDRF)

The delegation of the Federal Service for Surveillance in Healthcare headed by Mikhail Murashko, Head of Roszdravnadzor,…

03.17.2016
READ ARTICLE
new-img-8

Pharmaceuticals

Roszdravnadzor has suspended a series of the preparation “Paratsetomol-UBF”

Roszdravnadzor has suspended a series of the preparation “Paratsetomol-UBF” in which pills the metal wire was found.

05.18.2016
READ ARTICLE
new-img-9

Roszdravnadzor

Medical equipment stands idle in the Pskov region

Roszdravnadzor (RZN) statement: the expensive medical equipment for the total amount of 342 million rubles stands idle in…

05.19.2016
READ ARTICLE
new-img-10

Control

Hospital control Jewish autonomous region

Roszdravnadzor has audited the activity of the Regional Budgetary Public Health Facility “Central district hospital of Lenin”…

05.20.2016
READ ARTICLE